company background image

BLIRT WSE:BLR Stock Report

Last Price


Market Cap







28 May, 2022


Company Financials
BLR fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health5/6

BLR Stock Overview

BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry.

BLIRT Competitors













Price History & Performance

Summary of all time highs, changes and price drops for BLIRT
Historical stock prices
Current Share Pricezł14.05
52 Week Highzł17.80
52 Week Lowzł6.20
1 Month Change51.40%
3 Month Change84.87%
1 Year Change-19.71%
3 Year Change1,452.49%
5 Year Change842.95%
Change since IPO114.50%

Recent News & Updates

Shareholder Returns

BLRPL BiotechsPL Market

Return vs Industry: BLR exceeded the Polish Biotechs industry which returned -41.8% over the past year.

Return vs Market: BLR underperformed the Polish Market which returned -17.1% over the past year.

Price Volatility

Is BLR's price volatile compared to industry and market?
BLR volatility
BLR Average Weekly Movement16.1%
Biotechs Industry Average Movement7.0%
Market Average Movement6.8%
10% most volatile stocks in PL Market13.4%
10% least volatile stocks in PL Market4.5%

Stable Share Price: BLR is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: BLR's weekly volatility has increased from 11% to 16% over the past year.

About the Company

199475Marian Popinigis

BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry. It offers proteins and enzymes, such as proteinases, RNase inhibitors, polymerases, nucleases, ligases, and other proteins; and molecular biology reagents, including DNA and RNA extraction, PCR and real-time PCR, reverse transcriptions, and RNA related products. BLIRT S.A. was founded in 1994 and is headquartered in Gdansk, Poland.

BLIRT Fundamentals Summary

How do BLIRT's earnings and revenue compare to its market cap?
BLR fundamental statistics
Market Capzł246.25m
Earnings (TTM)zł7.57m
Revenue (TTM)zł39.77m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLR income statement (TTM)
Cost of Revenuezł5.68m
Gross Profitzł34.09m
Other Expenseszł26.52m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 11, 2022

Earnings per share (EPS)0.43
Gross Margin85.72%
Net Profit Margin19.02%
Debt/Equity Ratio0.001%

How did BLR perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is BLIRT undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: BLR (PLN14.05) is trading above our estimate of fair value (PLN4.69)

Significantly Below Fair Value: BLR is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: BLR is good value based on its Price-To-Earnings Ratio (32.5x) compared to the Polish Biotechs industry average (34.9x).

PE vs Market: BLR is poor value based on its Price-To-Earnings Ratio (32.5x) compared to the Polish market (10x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLR's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BLR is overvalued based on its Price-To-Book Ratio (9.3x) compared to the PL Biotechs industry average (3.8x).

Future Growth

How is BLIRT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIRT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BLIRT performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BLR has a high level of non-cash earnings.

Growing Profit Margin: BLR's current net profit margins (19%) are lower than last year (34.3%).

Past Earnings Growth Analysis

Earnings Trend: BLR has become profitable over the past 5 years, growing earnings by 75.1% per year.

Accelerating Growth: BLR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BLR had negative earnings growth (-66%) over the past year, making it difficult to compare to the Biotechs industry average (-6.2%).

Return on Equity

High ROE: BLR's Return on Equity (28.5%) is considered high.

Financial Health

How is BLIRT's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BLR's short term assets (PLN19.3M) exceed its short term liabilities (PLN4.8M).

Long Term Liabilities: BLR's short term assets (PLN19.3M) exceed its long term liabilities (PLN1.1M).

Debt to Equity History and Analysis

Debt Level: BLR has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BLR's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BLR's debt is well covered by operating cash flow (1603092.6%).

Interest Coverage: BLR earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is BLIRT current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BLR's dividend (7.12%) is higher than the bottom 25% of dividend payers in the Polish market (2.63%).

High Dividend: BLR's dividend (7.12%) is low compared to the top 25% of dividend payers in the Polish market (7.73%).

Stability and Growth of Payments

Stable Dividend: Too early to tell whether BLR's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if BLR's dividend payments are increasing as they only just started paying a dividend.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (231.7%), BLR's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (45582.5%), BLR's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Marian Popinigis



Mr. Marian Popinigis has been the Chief Executive Officer at BLIRT S.A. since July 2018. He is President of the Management Board at BLIRT S.A. Mr. Popinigis is a Co-Founder of Mercor S.A. and serves as its...

Leadership Team

Experienced Management: BLR's management team is considered experienced (2 years average tenure).

Board Members

Experienced Board: BLR's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

BLIRT S.A.'s employee growth, exchange listings and data sources

Key Information

  • Name: BLIRT S.A.
  • Ticker: BLR
  • Exchange: WSE
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł246.247m
  • Shares outstanding: 17.53m
  • Website:

Number of Employees


  • BLIRT S.A.
  • Trzy Lipy 3/1.38
  • Gdansk
  • 80-172
  • Poland


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.